

March 12, 2019



## **DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019**

MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31<sup>st</sup> Annual ROTH Conference March 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA. DiaMedica's President and CEO, Rick Pauls, will be hosting one-on-one meetings with institutional investors at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting.

### ***About DiaMedica Therapeutics Inc.***

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica's shares are listed on The Nasdaq Capital Market under the trading symbol "DMAC."

For more information, please visit [www.diamedica.com](http://www.diamedica.com).

### **Contact:**

Scott Kellen  
Chief Financial Officer  
Phone: (763) 496-5118  
[skellen@diamedica.com](mailto:skellen@diamedica.com)

Paul Papi  
Vice President of Business Development  
Phone: (617) 899-5941  
[info@diamedica.com](mailto:info@diamedica.com)



Source: DiaMedica Therapeutics Inc.